Introduction
Reporting guidelines have been developed to address concerns of poor quality in published research. These guidelines seek to improve methodological quality, encourage transparency and strengthen peer review [1, 2] . More specifically, it has been purported that implementing reporting guidelines may reduce selective outcome reporting, omission of important information from methods sections, inaccurate presentation of results and inadequate reporting of adverse events [3] . Hirst and Altman suggest that implementing reporting guideline adherence can reduce the rate of low-quality reporting and thus improve upon the current, potentially harmful effects of research [4] . Dissenting research suggests that practical barriers to guideline adherence are among the most important to journal editors. These include lack of time and resources to review guideline adherence by authors and potential lack of publisher support [5] . The EQUATOR (Enhancing the Quality of Transparency of Health Research) Network was established to support the development of reporting guidelines as well as raise awareness of the benefit of guideline use to all stakeholders [6] . The EQUATOR Network has already published 345 guidelines [7] to date, with popular guidelines such as Consolidated Standards of Reporting Trials (CONSORT), Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) being included in their library. Still, it has also been reported that in light of the rapid publication of new reporting guidelines, journal editors may not be well equipped to select the correct guideline for a specific study type.
Additionally, prospective clinical trial registration may limit the rate of selective reporting bias in reporting clinical trial outcomes. Jones et al. conducted a systematic review to examine the rate of selective outcome reporting problems across multiple fields of medicine and found that there is a high rate of discrepancy between registered and published outcomes [8, 9] . To address this issue, the International Committee of Medical Journal Editors (ICMJE) [10] and World Health Organization (WHO) [11] both recommend policies for prospective trial registration, with the Food and Drug Administration formally mandating trial registration in 2007 [12] . Given these considerations, there is evidence to suggest that adherence to reporting guidelines as well as trial registration may improve research quality.
Here, we investigate the policies of hematology journals concerning the adoption of reporting guidelines and registration of clinical trials and systematic reviews to understand the extent to which these journals use guidelines to improve study quality and reporting. Furthermore, we suggest ways in which the practical barriers preventing reporting guideline adherence could be avoided.
Methods
We conducted a systematic review of hematology journals' policies and guidelines for authors in order to examine the rates of guideline use and adherence. This study did not meet the regulatory definition of human subject research as defined in 45 CFR 46.102(d) and (f) of the Department of Health and Human Services' Code of Federal Regulations [13] and, therefore, was not subject to institutional review board oversight. PRISMA guidelines [14] for systematic review and SAMPL guidelines [15] We contacted the Editor-in-Chief of each journal to inquire about relevant accepted article types (systematic reviews/meta-analyses, clinical trials, diagnostic accuracy studies, case reports, epidemiological studies and animal studies). CW and CS corresponded with the Editors-inChief and employed Dillman's method for non-responding journals by e-mail once a week for 3 weeks to improve response rates [16] . Hematology 2015 provides review articles from the Education Program of the American Society of Hematology Annual Meeting and was, therefore, not contacted. Forty-three of 69 (62.3%) contacted journals responded. Five editorial e-mails from journal websites were not functioning.
A priori definitions were constructed by CW, MTS, and MV for the coding process. For each of the guidelines and registries, it was determined whether adherence by each journal was 'compulsory/required', 'recommended' or 'not mentioned.' In cases where it was unclear whether the journal followed a specific guideline or registry it was rated as 'unclear'. Keywords such as 'must', 'need' or 'manuscripts will not be considered for publication unless' were categorized as 'compulsory/required'. Similarly, keywords such as 'should', 'encouraged' and 'prefer' were categorized as 'recommended'. Statements that were extracted in a language other than English were translated using Google Translate (Google Inc, Mountain View, CA, USA).
Impact factors for all included journals were retrieved with the help of a medical librarian. We categorized geographical zone into the following groups: North America (including the USA and Canada), the UK, Europe (excluding the UK) and Other (including all remaining countries).
Our primary analysis was to compare the information extracted from journal websites and cross-reference it with accepted article types from each journal, confirmed by Editor-in-Chief e-mail response. If a journal did not accept a specific article type, we excluded that guideline from our analysis of that journal (i.e. if a journal did not accept animal studies, ARRIVE guidelines were not considered in the analysis of that journal).
If an e-mail response was not received after three attempts we made no judgments regarding the journal's types of accepted articles. Our rationale was that, although the websites of these journals list accepted article types, we found evidence of these lists being out of date in some cases and vague in others. For example, many websites list simply 'Original Research' and we were unable to interpret that for our purposes. For these journals we report only the accepted reporting guidelines and policies.
Results
Seventy hematology journals were identified, with Hematology 2015 being excluded for providing review articles from the Education Program of the American Society of Hematology Annual Meetings. The Editor-in-Chiefs of Current Opinion in Hematology and Current Hematologic Malignancy Reports confirmed that these journals do not accept any of the article types we inquired about and were therefore excluded from our analysis. The 67 remaining journals are listed in Tables 1 and 2 . The impact factor for included journals ranged from 0.101 to 11.019 (mean = 3.07, standard deviation [SD] = 2.21), with Lancet Hematology and Journal of Hematopathology not listing an impact factor at the time of analysis. Editorial offices of included journals were located mostly in North America (37/67, 55.2%), followed by the UK (15/67, 22.4%), Europe (excluding the UK) (11/67, 16.4%) and Other (4/67, 6.0%). The EQUATOR Network was referenced by only three (4.5%) journals, whereas ICMJE guidelines were referenced by 39 (58.2%) journals. The forty-three journals that responded to our e-mail inquiries had an average impact factor of 3.32, whereas those that did not respond averaged 2.64. The overall average impact factor of included hematology journals was 3.07.
Forty-eight per-cent (32/67) of all included journals did not mention any reporting guidelines in their Instructions for Authors section. Concerning responding journals, the CONSORT statement was mentioned by 16 of 40 (40.0%) journals: 4/40 (10.0%) required adherence, 11/40 (27.5%) recommended adherence and 1/40 (2.5%) was unclear in the instructions to authors. MOOSE guidelines were mentioned by only one of 34 (2.9%) journals, with the instruction to authors regarding adherence being unclear. QUOROM guidelines were only mentioned by one of 40 (2.5%) journals and were recommended. The PRISMA statement was mentioned by five of 40 (12.5%) journals: one (2.5%) required adherence, two (5.0%) recommended adherence and two (5.0%) were unclear in their instructions. STARD guidelines were mentioned by three of 33 (9.1%) journals: one (3.0%) required adherence, one (3.0%) recommended adherence and one (3.0%) was unclear in the instructions to authors. The STROBE statement was mentioned by four of 34 (11.7%) journals: one (2.9%) required adherence, two (5.8%) recommended adherence and one (2.9%) was unclear in the instructions to authors. ARRIVE guidelines were mentioned by six of 39 (15.4%) journals: four (10.3%) required adherence and two (5.1%) recommended adherence. CARE guidelines were mentioned by one of 31 (3.2%), with adherence being recommended.
ClinicalTrials.gov trial registration was mentioned by eight of 40 (20.0%) journals: one (2.5%) required adherence, six (15.0%) recommended adherence and one (2.5%) was unclear in the instructions to authors. Likewise, WHO trial registration was mentioned by eight of 40 (20.0%) journals: two (5.0%) required adherence, four (10.0%) recommended adherence and two (5.0%) were unclear in their instructions to authors. Generic trial registration in general was mentioned by 15 of 40 (37.5%) journals: 12 (30.0%) required adherence, two (5.0%) recommended adherence and one (2.5%) was unclear in the instructions to authors. PROSPERO registration for systematic reviews was mentioned by one of 40 (2.5%) journals, with adherence being recommended. Cochrane registration for systematic reviews was mentioned by three of 40 (7.5%) journals, with all three recommending adherence.
Incidentally, the Journal of Hematology and Oncology recommended STARD guidelines; however, the editorial e-mail response confirmed that diagnostic accuracy studies are not accepted.
Discussion
Our systematic review of hematology journals' Instructions for Authors pages found that 47.8% of hematology journals included in our study did not mention adherence to any guidelines. Additionally, we found that three guidelines (MOOSE, QUOROM and CARE) were only mentioned by one journal. In the case of QUOROM, this is to be expected given that the PRISMA guidelines have replaced QUOROM. However, this means that one journal in our sample is still suggesting that authors adhere to an outdated reporting guideline.
Reporting guidelines, trial registration and systematic review registration were rarely used by hematology journals. The CONSORT statement (40.0%) and generic trial registration (37.5%) were mentioned most often. Policies regarding systematic review registration were almost completely absent from the hematology journals' instructions pages, even though nearly all the included journals accept systematic reviews.
Previous studies have been conducted in pediatric and surgery journals [17, 18] that investigate the Instructions for Authors pages of journals indexed in the Journal Reporting guideline adherence in hematology 611 To assist authors in adhering to guidelines and policies, editors must ensure that their journal websites are clear and concise with regards to which types of studies are accepted and what the expectations are for authors when submitting for publication. There are reasons why a journal's website might not be up-to-date with the accepted studies, as our study found that some editors mentioned newly accepted study types that were not yet described in their instructions for authors. Additionally, the types of included articles must be explicitly stated as well. We frequently found journal websites stating 'Original Research' was acceptable, without elaborating further. Clarity on behalf of a journal is essential to establish transparency, in order to more readily evaluate the adherence to reporting guidelines and policies.
Lack of adherence to reporting guidelines, clinical trial registration and systematic review registration allows the possibility for biased studies to be published. Some authors argue that ethical reporting on the part of authors is a moral obligation to the readers because patients have consented to participate in research and funding has been provided for the study at hand [19, 20] . A biased study that is published does a disservice to the readers, because introducing bias into the literature blinds readers and prevents them from performing a proper scientific evaluation of a study's methodology and results [19, 20] .
Efforts have been made to improve the quality and validity of scientific research, most notably in 2006 when the EQUATOR Network was established [7] . EQUATOR provides access to hundreds of reporting guidelines, and with the support of major editorial groups, many of these guidelines have become a requirement in many high impact factor journals [21] . Indeed, it has been reported that adoption of reporting guidelines improves a journal's quality of reporting of critical elements [22] . Although adopting guidelines does strengthen quality of reporting [23] , it is reasonable to assume that this strengthening might be occurring more rapidly in higher impact factor Responding journals.
• = required/compulsory; † = recommended; ? = unclear. Boxes filled with grey: journal does not accept the study design requiring these guidelines. Boxes filled with red: journal does not accept the study design, yet the instructions for authors mention the guideline. Non-responding journals.
• = required/compulsory; † = recommended; ? = unclear. Italicized journal name:
does not mention any guidelines.
hematology journals, as lower impact factor journals do not exhibit comparable rates of guideline adoption, according to our sample. This probably adds to the disparity in quality of reporting in higher vs. lower impact factor journals. Trial registration also plays an important role in limiting bias. The BMJ recently published an article authored by several medical journal editors which stated that trial registration is the single most important tool in ensuring unbiased reporting [24] . [12] . Despite this federal mandate, many are reluctant to endorse and enforce trial registration completely [25] [26] [27] . There are major discrepancies between reported trial registration in ICMJE member journals [28] and other journals [29] , with the ICMJE member journals showing 96% trial registration and the other journals showing 39% registration.
Understandably, the ability of journal editors to monitor the adherence to reporting guidelines is diminished because of limited resources, although adoption of these guidelines can only assist in improving reporting quality. Future research might find it meaningful to investigate the practical aspects of guideline adherence. Certain reporting guidelines, such as CONSORT for randomized controlled trials, are well known among our sample and many journals adhere to this guideline. However, studies have shown that in top general medicine journals that require author adherence to the 19-item CONSORT checklist, there is variable adherence of greater than 25% on eight of the 19 checklist items [30] . This suggests that a journal requiring adherence does not necessarily translate to author adherence. A means of bridging this gap could be to require authors to submit a completed checklist with submission of their articles so that reviewers are only required to confirm the checklist rather than complete it. Furthermore, it has been suggested that Institutional Review Boards (IRBs) could be utilized in increasing the rate of trial registration [31] . We suggest that IRBs comply with this suggestion, but broaden their scope to other guidelines. Increasing guideline adherence ensures that journal requirements are complied with, and it is impractical to require reviewers and editors to be the ones policing guideline adherence. Any study requiring IRB approval could be screened for adherence to proper guidelines, thus reducing the work required for reviewers and editors.
Many journal editors feel that with the amount of guidelines now available, choosing the correct guideline for a specific study type is a practical barrier to guideline adherence [5] . The EQUATOR Network has gone to great lengths to assist editors and reviewers in this area. The EQUATOR Network's website [7] features key reporting guidelines for popular study types on its main page, as well as free tools to assist editors, reviewers and authors in choosing an appropriate guideline for a particular study type. These tools make guideline selection more manageable for all parties and help remove this practical barrier to use.
Another option for all medical journals is to subscribe to Penelope [32] . Penelope is a subscription-based tool that can be used by medical journals to automatically check submissions for adherence to reporting guidelines, proper statistical reporting, correct formatting, and much more. Penelope can be customized to fit the needs of a specific journal and could make checking for adherence faster and easier.
In conclusion, reporting guidelines are infrequently required or recommended in hematology journals, as is adherence to policies regarding registration of clinical trials and systematic reviews. We recommend adoption of these guidelines and policies by hematology journals in order to strengthen the quality of hematology research. A first step in the process could be recommending guidelines and trial registration, as research continues to be carried out to gauge the effectiveness of these guidelines in minimizing bias and maximizing reporting. Additionally, we have suggested ways to reduce the time required for editors and reviewers to enforce the adherence to reporting guidelines. A joint effort is required between guideline developers, editors, reviewers and authors, along with considerations of practical concerns. 
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